相关实验视频

Updated: Feb 28, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

一种新型的PPARG R212W变体导致家族局部脂质疏松症3型:临床表现和功能特征

Yuan Gao¹, Ningyi Song¹, Lina Fu¹

¹Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Hubei Provincial Clinical Research Center for Children's Growth and Development and Metabolic Diseases, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

International journal of molecular sciences

|February 27, 2026

概括

一种新的PPARG基因变异,R212W,通过破坏PPARγ蛋白的稳定性,导致家族局部脂质缩3型 (FPLD3). 这导致线粒体功能障碍和代谢问题,提供潜在的治疗点.

科学领域:

遗传学是一个遗传学.
分子生物学分子生物学
内分泌学在内分泌学.

背景情况:

3型家族局部脂质缩症 (FPLD3) 是一种罕见的遗传疾病.
它是由PPARG基因突变引起的,影响脂肪分布和新陈代谢.
由于代谢综合征和代谢综合征的症状重叠,临床诊断很困难.

研究的目的:

识别和功能性地描述一个新型的PPARG变异在一个中国家庭与FPLD3.
阐明已识别的变种的致病机制.
探索潜在的治疗策略.

主要方法:

整体外因子测序和桑格测序来识别变体.
在模拟中,酶记者测定和蛋白质稳定性分析 (循环胺追逐).
细胞模型 (脂肪细胞) 来评估线粒体功能 (JC-1染色) 和基因表达,有或没有罗西格利塔治疗.

主要成果:

一种新型异构的PPARG c.634C>T (p.Arg212Trp,R212W) 变体被确定并与FPLD3表型分离.
R212W突变显示转录活性降低 (~40%) 和蛋白质稳定性显著下降.
R212W表达损害了线粒体功能,降低了ATP水平,并降低了脂肪细胞中关键代谢基因的调节,部分由罗西格利塔拯救.

结论:

一种新的致病性PPARG R212W变种与FPLD3.3有关.
致病机制涉及蛋白质不稳定,线粒体功能障碍和生物能量失效,而不仅仅是功能丧失.
罗西格利塔的部分救援表明了FLPD3.3的潜在治疗方法.

关键词:

在 PPARG 里面.在R212W突变中.3型家族局部脂质缩症 (FPLD3) 是一种家族局部脂质缩症.胰岛素耐药性是一种胰岛素耐药性.线粒体功能障碍线粒体功能障碍蛋白质的稳定性蛋白质的稳定性罗西格利塔 (Rosiglitazone) 是一种葡萄素.

更多相关视频

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...